CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
非霍奇金淋巴瘤患者中 CAR-T 细胞治疗后高失败风险且符合桥接放疗条件者的比例
英文原题：Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy.
查看英文原题
Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
约 47%（38/81）的患者在 CAR-T 后被归类为高复发风险，其病灶可纳入标准放疗计划，并符合桥接 RT 研究的条件。
研究思路结论见上方概要
背景
本研究的目的是确定符合CD19 CAR-T 细胞治疗（CAR-T）后早期复发高风险标准的复发/难治性（R/R）非霍奇金淋巴瘤（NHL）患者中，其病灶可被标准放疗（RT）计划覆盖（定义为<5个恶性病灶）且可能从CD19 CAR-T 前桥接RT中获益的患病率。
方法
这是一项单中心回顾性研究，纳入2018年至2022年期间接受CD19 CAR-T 治疗的R/R NHL患者。符合条件的患者需有可用的单采前影像学检查。所有患者根据病灶数量和高危疾病标准史进行分类：大包块疾病10 cm、1个结外（EN）部位、LDH正常，或1个病灶SUVmax 10。
结果
共评估了81例R/R NHL患者。根据我们的定义，40例（49%）患者符合桥接RT的条件，包括38例符合高风险标准的患者：31例有1个EN部位，19例有1个SUVmax 10的病灶，16例有大包块疾病，3例有LDH升高。CAR-T 后3个月时，采血前研究中<5个病灶、5个病灶和无病灶的高风险患者的ORR分别为76%（CR 69%，PR 7%）、70%（CR 60%，PR 10%）和80%（CR 80%）。
展开英文摘要原文
MATERIALS AND METHODS
This is a single-center, retrospective study of patients with R/R NHL who received CD19 CART from 2018 to 2022. Eligible patients had pre-apheresis radiologic studies available. All patients were classified by number of lesions and history of high-risk disease criteria: bulky disease 10 cm, 1 extranodal (EN) sites, LDH normal, or 1 lesion with SUVmax 10.
RESULTS
A total of 81 patients with R/R NHL were evaluated. Based on our definition, 40 (49%) patients would have been eligible for bridging RT, including 38 patients who met high-risk criteria: 31 with 1 EN site, 19 had 1 lesion with SUVmax 10, 16 with bulky disease, and 3 with elevated LDH. At 3 months after CART, ORRs in high-risk patients with <5 lesions, 5 lesions, and no lesions on pre-apheresis studies were 76% (CR 69%, PR 7%), 70% (CR 60%, PR 10%), and 80% (CR 80%), respectively.
CONCLUSION
Approximately 47% (38/81) of patients were classified as at high risk of relapse after CART with disease encompassable in a standard radiation plan and eligible for bridging RT studies.
论文信息
- 作者
- Danish A、Della Pia A、Fogel L、Alkhatatneh H、Zhao C、Varughese T、Al Feghali KA、Pascual L
- 单位
- John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, United States.United States
- 期刊
- Frontiers in oncology2024
- 原文标识
- PubMed 39228984 · DOI 10.3389/fonc.2024.1425506
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →